Eli Lilly and Company
$1,347.11-$4.01 (-0.3%)
Last close · Data as of Nov 20, 2026
- Market cap
- $1.00T
- P/E
- 48.6x
- EV / EBITDA
- 32.8x
- Revenue
- $65.2B
- Net margin
- 31.7%
- ROCE
- 38.4%
Price chart
Technical chartScreen technicals →+29.1% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +4.9%
- 3M
- +8.3%
- 6M
- +32.2%
- 1Y
- +29.1%
- 5Y
- +416.7%
52-week range
Day change -$4.01 (-0.3%) from $1,351 to $1,347 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in LLY, bought on each weekday since 2021.
News & filings
What Eli Lilly and Company filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthOperating profit was 38.0 times interest costs.
Concerns (1)
- The P/E of 48.6 is 101% above the peer median of 24.2.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Read moreShow less
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
- Sector
- Healthcare
- Shares outstanding
- 894.8M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $1.00T
- P/E
- 48.6x
- P/B
- 37.8x
- EV / EBITDA
- 32.8x
- EV / Sales
- 15.9x
- P/S
- 15.4x
- 52-week high
- $1,443.50
- 52-week low
- $851.21
Profitability
- Operating margin
- 45.6%
- Net margin
- 31.7%
- EBITDA margin
- 48.6%
- ROE
- 77.8%
- ROCE
- 38.4%
- ROA
- 18.4%
- Asset turnover
- 0.58
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $65.2B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 44.7%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 31.7%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 94.9%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $6.0B
Solvency
- Current ratio
- 1.58
- Debt / Equity
- 1.60
- Debt / Assets
- 0.38
- CFO / Net profit
- 0.81
- Cash / Market cap
- 0.7%
Where the revenue went
Of every $100 of FY2025 revenue, $32 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $11.1B |
| Revenue | Gross profit | $54.1B |
| Gross profit | Research and development | $13.3B |
| Gross profit | Selling, general and administrative | $11.1B |
| Gross profit | Operating income | $29.7B |
| Operating income | Pretax income | $25.7B |
| Operating income | Interest and other expense | $4.0B |
| Pretax income | Tax and other | $5.1B |
| Pretax income | Net income | $20.6B |
Revenue and net profit
Revenue grew 44.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $28.5B | $6.2B |
| FY2023 | $34.1B | $5.2B |
| FY2024 | $45.0B | $10.6B |
| FY2025 | $65.2B | $20.6B |
Cash flows
FY2025: $16.8B from operations, $6.0B free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $7.6B | $4.6B |
| FY2023 | $4.2B | -$3.2B |
| FY2024 | $8.8B | $414.0M |
| FY2025 | $16.8B | $6.0B |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $65.2B+44.7%1Y
- EBITDA
- $31.7B+68.5%1Y
- Net profit
- $20.6B+94.9%1Y
- Cash from operations
- $16.8B+90.7%1Y
- Free cash flow
- $6.0B+1,340.6%1Y
- Revenue CAGR, 3Y
- 31.7%
- Net profit CAGR, 3Y
- 49.0%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $65.2B | $31.7B | $20.6B | $6.0B | 77.8% | +44.7% | +94.9% |
Monthly returns
Month-by-month returns of LLY across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $112.5B |
| Current assets | $55.6B |
| Non-current assets | $56.8B |
| Liabilities | $85.9B |
| Current liabilities | $35.2B |
| Non-current liabilities | $50.7B |
| Equity | $26.5B |
| Paid-in capital | $7.3B |
| Retained earnings | $24.5B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; LLY highlighted.
P/E against peers
LLY trades at 48.6x earnings against a peer median of 24.2x (a 101% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Eli Lilly and CompanyLLYthis companyP/E ↑ premium | $1.00T | 48.6x | 37.8x | 77.8% | 32.8x |
| Johnson & JohnsonJNJ | $549.3B | 20.5x | 6.7x | 32.9% | 14.1x |
| AbbVie Inc.ABBV | $397.4B | 94.9x | — | -128.0% | 26.1x |
| UnitedHealth Group IncorporatedUNH | $360.1B | 29.9x | 3.8x | 12.8% | 18.0x |
| Merck & Co., Inc.MRK | $297.0B | 16.3x | 5.6x | 34.7% | 11.7x |
| Amgen Inc.AMGN | $186.5B | 24.2x | 21.5x | 89.1% | 13.7x |
| Thermo Fisher Scientific Inc.TMO | $179.1B | 26.7x | 3.4x | 12.6% | 18.1x |
| Gilead Sciences, Inc.GILD | $160.4B | 18.8x | 7.1x | 37.5% | 12.9x |
| Abbott LaboratoriesABT | $158.1B | 24.2x | 3.0x | 12.5% | 13.5x |
| Peer median | — | 24.2x | 5.6x | 22.8% | 13.9x |
Year-to-date ROI
LLY since 1 January, against earlier years.
Historical volatility
LLY's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 29.0% |
| FY2023 | 30.3% |
| FY2024 | 37.8% |
| FY2025 | 45.6% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $65.2B |
| Cost of revenueCost Of Revenue | $11.1B |
| Gross profitGross Profit | $54.1B |
| Operating expensesOperating Expense | $24.4B |
| Research and developmentResearch And Development | $13.3B |
| Selling, general and administrativeSelling General And Administration | $11.1B |
| Total expensesTotal Expenses | $35.5B |
| Operating incomeOperating Income | $29.7B |
| Interest and other | |
| Pretax incomePretax Income | $25.7B |
| TaxTax Provision | $5.1B |
| Net incomeNet Income | $20.6B |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $112.5B |
| Current assetsCurrent Assets | $55.6B |
| Non-current assetsTotal Non Current Assets | $56.8B |
| LiabilitiesTotal Liabilities Net Minority Interest | $85.9B |
| Current liabilitiesCurrent Liabilities | $35.2B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $50.7B |
| EquityTotal Equity Gross Minority Interest | $26.5B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $16.8B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $16.8B |
| Net income, continuing operationsNet Income From Continuing Operations | $20.6B |
| Depreciation and amortisationDepreciation And Amortization | $2.0B |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $2.0B |
| Stock-based compensationStock Based Compensation | $626.0M |
| Deferred taxDeferred Tax | -$1.7B |
| Deferred income taxDeferred Income Tax | -$1.7B |
| Operating gains and lossesOperating Gains Losses | -$180.0M |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | -$180.0M |
| Gain loss on sale of businessGain Loss On Sale Of Business | — |
| Change in working capitalChange In Working Capital | -$8.1B |
| Other non-cash itemsOther Non Cash Items | $3.5B |
| Investing cash flowInvesting Cash Flow | -$11.0B |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$11.0B |
| Capital expenditureCapital Expenditure | -$10.8B |
| Purchase of PP&EPurchase Of PPE | -$7.8B |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$7.8B |
| AcquisitionsPurchase Of Business | -$661.0M |
| DisposalsSale Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$661.0M |
| Purchase of investmentsPurchase Of Investment | -$645.0M |
| Sale of investmentsSale Of Investment | $964.0M |
| Net investment purchases and salesNet Investment Purchase And Sale | $319.0M |
| Purchase of intangiblesPurchase Of Intangibles | -$3.0B |
| Sale of intangiblesSale Of Intangibles | $218.0M |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$2.8B |
| Other investing changesNet Other Investing Changes | $1.0M |
| Financing cash flowFinancing Cash Flow | -$2.2B |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$2.2B |
| Debt issuedIssuance Of Debt | $13.2B |
| Debt repaidRepayment Of Debt | -$778.0M |
| Net debt issuedNet Issuance Payments Of Debt | $8.1B |
| Net short-term debt issuedNet Short Term Debt Issuance | -$4.3B |
| Long-term debt issuedLong Term Debt Issuance | $13.2B |
| Long-term debt repaidLong Term Debt Payments | -$778.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | $12.4B |
| Net common stock issuedNet Common Stock Issuance | -$4.1B |
| Common stock repurchasedCommon Stock Payments | -$4.1B |
| Share buybacksRepurchase Of Capital Stock | -$4.1B |
| Dividends paidCash Dividends Paid | -$5.4B |
| Common dividends paidCommon Stock Dividend Paid | -$5.4B |
| Other financing chargesNet Other Financing Charges | -$772.0M |
| Change in cashChanges In Cash | $3.6B |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 37,200.0% |
| Cash at the start of the yearBeginning Cash Position | $3.3B |
| Cash at the end of the yearEnd Cash Position | $7.3B |
| Free cash flowFree Cash Flow | $6.0B |
Learn while you research
Academy chapters picked for Eli Lilly and Company and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Valuation Multiples ExplainedThis stock trades at a P/E of 48.6, learn when high multiples are justified.6 min read
- 03 Growth Investing45% revenue growth is in the top tier, learn how to value growth.7 min read
- 04 Leverage RatiosDebt/Equity of 1.60 is elevated, understand what that means for solvency.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read